United Therapeutics: FDA accepts supplemental NDA for nebulized Tyvaso
United Therapeutics said the FDA accepted a supplemental new drug application for nebulized Tyvaso to treat idiopathic pulmonary fibrosis.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.